Building on the legacy of many, I'm incredibly excited that we have successfully translated our polygenic risk scores into a validated clinical assay Mass General Brigham Broad Institute, orderable by any clinician in the US today. 🧬To order: massgeneralbrigham.org/en/research-an… 🧬Announcement:

More incredible #CRISPR data with #Nexz published today in NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE.

Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx jacc.org/doi/10.1016/j.… #HFSA2025 #JACC

Discover the latest advancements in the field of #amyloidosis! 📚 From genomic screening to transthyretin amyloidosis and aortic stenosis, #JACCCardioOnc's Amyloidosis Hub covers it all. bit.ly/4o06pK0 #ACCMidEast #CardioOnc #ATTR #vhdAS Bonnie Ky, MD, MSCE, FACC American College of Cardiology

Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. Read this State-of-the-Art review just published in #EHJ European Society of Cardiology European Society of Cardiology Journals #HCM academic.oup.com/eurheartj/adva…

ODYSSEY-HCM: Mavacamten shows no significant improvement in outcomes for patients with symptomatic nonobstructive #cvHCM. Drs. Matt Martinez and Milind Desai explore the findings and discuss future treatment of HCM on this episode of 🎧 ACCEL Lite: bit.ly/4oeaTwG

Patterns of Nonspecific Myocardial FDG Uptake in Patients Without Sarcoidosis With Normal CMR — Beware, not all FDG uptake on CardiacPET is cardiac sarcoidosis. jacc.org/doi/10.1016/j.…

Raging against the Machine: The Human Side of the Story | NEJM AI ai.nejm.org/doi/full/10.10…

Explore the role of #cvImaging in early stages of #HFpEF in this #JACCIMG state-of-the-art review: crucial for timely diagnosis and intervention. jacc.org/doi/10.1016/j.… Hide Yaku, MD, PhD, FHFSA

𝗣𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝗧𝗿𝗮𝗶𝗻𝗲𝗲𝘀 𝗳𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗨𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 Uncertainty is ubiquitous in medical practice yet is often viewed as a regrettable phenomenon to be tolerated or eradicated. To prepare trainees for practice, teachers need to reframe uncertainty

Uncertainty is ubiquitous in the practice of medicine. A new review characterizes clinical uncertainty and shows how teachers can guide learners to recognize, manage, and communicate uncertainty in practice. Figure 1 from the review shows a conceptual model of how clinicians

This is an important case for diastolic function assessment that was corrected in 2025 guideline. A main lesson is " Diastolic Function can be normal with reduced EF and/ or myocardial infarction." We should not adjudicate diastolic dysfunction based on clinical data. Always use

New ACC Concise Clinical Guidance updates best practices for diagnosing and managing transthyretin amyloid #cardiomyopathy, highlighting disease-modifying and HF therapies plus future directions. jacc.org/doi/10.1016/j.… #JACC #Amyloidosis #ATTRCM #HeartFailure

A scientific first! ANGPTL3 in vivo gene editing in a ph1 trial is feasible & appears to lower LDL-C by 50% and TGs by 55% among individuals with resistant hyperlipidemia. nejm.org/doi/full/10.10… NEJM #AHA25 Efficacy appears similar to zodasiran (ANGPTL3 siRNA)

VESALIUS-CV results show evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous #cvMI or #stroke compared with placebo. Read more in our #AHA25 coverage: bit.ly/4oBNohQ #CardioX

Bad news for enthusiasts of left atrial appendage closure from #AHA25. CLOSURE-AF is not yet published, but reports from New Orleans indicate inferiority compared with best medical care (the trial was designed for non-inferiority, making this the most unexpected and unfavorable

PISCES: Among 1228 pts on HD, 4g omega-3 fatty acids vs corn oil placebo led to reduction in serious CV events (HR 0.57!). nejm.org/doi/full/10.10… NEJM This is on the background of null STRENGTH (4g omega-3 carboxylic acids vs corn oil in high CV risk pts

Original Article: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 nej.md/43doGvu AHA Science | #AHA25

(1/14) 🚨I had the privilege of providing commentary on the Phase 2 #coramitug trial at #AHA25. The headline was that patients who received high-dose (60 mg/kg) coramitug had significant reductions in NT-proBNP at 1 year compared with placebo. So it’s an unequivocal win, right?

New study in the NEJM shows #olezarsen (ApoC-III antisense) cut triglycerides by up to ~70% and reduced acute pancreatitis in patients with severe hypertriglyceridemia (TG ≥500 mg/dL). This moves ApoC-III inhibition beyond rare FCS, pointing to a much wider role in severe